MYO News and Press, Myomo Inc. From 05/08/24

2024-05-08 22:03:09 ET Myomo, Inc. (MYO) Q1 2024 Earnings Conference Call May 08, 2024 04:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Partici...

2024-05-08 16:33:11 ET More on Myomo Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid Myomo, Inc.: In Motion To Accelerating Revenue Growth Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript Myomo gets first lump sum reimbursements for M...

Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today ...

2024-05-06 10:14:46 ET More on Myomo Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid Myomo, Inc.: In Motion To Accelerating Revenue Growth Seeking Alpha’s Quant Rating on Myomo Read the full article on Seeking Alpha For f...

Claims Remitted for Payment by All Four Billing Regions Orthotics and Prosthetics Providers Beginning to Receive Reimbursement at Published Rates Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that...

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for th...

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its ...

2024-03-13 06:55:06 ET Summary Myomo offers revolutionary MyoPro braces that enhance mobility for upper limb disabilities due to various neurological conditions. The company is experiencing a record number of orders, leading to sustainable revenue growth and expansion in the Chine...

2024-03-10 03:00:22 ET Summary Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change. MYO revenue growth is poised to accelerate further...

2024-03-07 20:10:08 ET Myomo, Inc. (MYO) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chairman & Chief Executive Officer Dave Henry - Chief Financial Officer Confere...